A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism

Provide respiratory support as needed; control congestive heart failure and arrhythmia; control fever, hypoglycemia, and fluid loss as necessary. Large doses of antithyroid drugs (e.g., methimazole or propylthiouracil) followed in one to two hours by large doses of iodine may be given to inhibit synthesis and release of thyroid hormones. Plasmapheresis, charcoal hemoperfusion and exchange transfusion have been reserved for cases in which continued clinical deterioration occurs despite conventional therapy. Because T4 is highly protein bound, very little drug will be removed by dialysis. In patients with congenital hypothyroidism, the adequacy of replacement therapy should be assessed by measuring both serum TSH (using a sensitive assay) and total- or free- T4.

More Info on this Drug

In this analysis, the sample size was considerably reduced (containing only 21% of the base case cohort), which may contribute to statistical uncertainty. Also, the patients in this subcohort may have multiple TSH values due to titration efforts, which our study did not further explore. After matching, the Synthroid and GL cohorts were balanced on baseline characteristics (Tables 1, 2).

TSH Suppression in Well-differentiated Thyroid Cancer and Thyroid Nodules

The methodological design followed previous designs employed by Merck to determine the bioequivalence of the new Eutirox® formulation in 2017 and 2019, adjusted to the new FDA potency specification 13. Rectal administration is an alternative route to treat hypothyroidism in patients who are unable to take oral formulations. The indications for rectal administration include short bowel syndrome and gastrointestinal tract obstruction. Since LT4 suppositories are not available in most medical institutions, IV LT4 preparations or extemporary tablet-dissolved solutions can be alternatives.

The unit‐dose containers allow delivery of the exact dose of the oral solution, thus minimizing the risks related to drops count or use of a pipette.
Concomitant administration of levothyroxine and sympathomimetic agents to patients with coronary artery disease may precipitate coronary insufficiency.
Lots of medications, food and beverages have been reported to impair the bioavailability of levothyroxine.
The relative bioavailability of SYNTHROID tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%.
T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans.

Levothyroxine

LT4 sodium salt is stored in a lucifugal bottle and mixed with saline before injection. The enterohepatic circulation plays a role in the absorption and metabolism of LT4. After absorption, most LT4 molecules are transported via the mesenteric and portal veins to the liver, where 17% of absorbed LT4 is estimated to be taken up (29). In the liver, some circulating LT4 molecules undergo conjugation, which enhances their water solubility.

The ratio of the geometrical least squares means for the log-transformed pharmacokinetics parameters was analyzed and the 90% confidence interval was determined. The bioequivalence limits (0.90–1.11) for AUC0−t and Cmax were established by celebrex synthroid applying the Schuirmann test. Those statistical procedures that did not exceed the 5% level of significance and among those with the lowest risk of erroneously rejecting the equivalence between formulations were accepted. The analysis of variance (ANOVA) evaluated the effect of the sequence and the individuals on AUC0−t and Cmax for each formulation. Phoenix® WinNonlin® version 8.2 software (Certara USA, Inc., Princeton, NJ) was used.

Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy.
In addition, the efficacy of TSH suppression for benign nodular disease is controversial.
Since ∼70% of oral LT4 is absorbed in the duodenum, jejunum, and ileum, jejunostomy and bowel resection lead to a substantial decrease in drug absorption (52).
Thirty‐six subjects were randomized and dosed in this study; of these, 31 completed all study periods.
Some included studies have intrinsic problems and well-designed studies with larger samples are expected to provide more solid evidence on the drugs interaction of LT4.

Medical

First, liquid solutions can be used to treat patients who have difficulty swallowing, such as pediatric patients. Liquid solutions can be administered with milk for infants with congenital hypothyroidism without obvious food interference. Notably, the dose may be reduced, since liquid LT4 at an equivalent dose can lead to increased TSH suppression (192). In addition, a liquid LT4 formulation can be administered directly through feeding tubes in patients receiving enteral feeding, and thus are preferred by nurses due to their convenience (193). The oral administration of a solution via a feeding tube is also a preferred option for patients with myxedema coma when IV LT4 is unavailable (194). Although the predominant treatment of thyroxine supplementation is LT4 monotherapy, 10% to 15% of patients have persistent or recurrent hypothyroid symptoms (weight gain, fatigue, memory loss, etc.) despite normal TH levels and medical adhesion (142, 143).

Genetic mutations of thyroid-specific proteins also play a role in the development of fetal goiters (249–251).
Dosage titration is based on serum TSH or free-T4 see Dosage and Administration (2.2).
From a conventional clinical perspective, doctors should instruct patients not to change preparations if the change will not result in obvious benefits.
The goal of treatment in pediatric patients with hypothyroidism is to achieve and maintain normal intellectual and physical growth and development.
Thyroxine hormone has been recognised since the early part of the nineteenth century and levothyroxine has been available since the mid-nineteenth century as a replacement for deficient thyroid hormones.

After vortex mixing, all the samples were centrifuged at approximately 2000g for 5minutes at room temperature. A 900‐μL aliquot of each sample was then transferred onto an extraction plate preconditioned with methanol and 0.1N hydrochloric acid. The aliquots in the extraction plate were evaporated under vacuum and washed with 400 μL of methanol and 400 μL of 0.1N hydrochloric acid.

A study has been conducted to compare the bioavailability of levothyroxine sodium oral solution and levothyroxine sodium soft capsule in healthy volunteers under fasting conditions. In each period, according to the randomization scheme, subjects were administered single oral doses of either test, as 4 × 150-μg unit-dose ampules, with or without water, or reference, as 4 × 150-μg capsules in a crossover design. Thirty-six subjects were randomized and dosed in this study; of these, 31 completed all study periods. When comparing the solution with the capsule (both products administered with water), the 90% confidence intervals for the ratio of log-transformed values of AUC0-48 and Cmax were within 90.00% and 111.11%, respectively, for baseline-corrected levothyroxine.

The majority of patients can achieve biological euthyroidism with oral LT4 supplements. In the past 15 years, novel formulations (liquid solutions and soft gel capsules) have been introduced to the market and have shown superior efficacy. These preparations potentially circumvent malabsorption induced by interfering medications and concomitant diseases and improve patient adherence.

Liquid Solution and Soft-Gel Capsule

There are several methodological differences between this study and the current one that may explain these findings (e.g., time windows for goal assessment; width of the reference range; composition of cohorts). All-cause and hypothyroidism-related HCRU and costs were also separately compared between patients who were persistent and who achieved target TSH levels during follow-up vs. those who did not achieve target TSH levels (achievers vs. non-achievers). Taking LT4 at bedtime (e.g. 3 h after the evening meal) rather than in the morning modestly but significantly increased LT4 levels and reduced TSH levels in the blood 23. Consequently, it has been proposed to move the routine administration of LT4 from morning to evening, especially as a range of secondary measures (creatinine, lipids, body mass index, heart rate, quality of life) were unchanged between morning and bedtime administration. However, the usually recommended time of intake of LT4 remains in the morning (but at least 30 min before consumption of tea, coffee, or breakfast).